NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)
ID: 333695Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/333695

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-21-237.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)" aimed at encouraging investigator-initiated efficacy clinical trials focused on neurological disorders. This initiative seeks to support trials that evaluate drugs, biologics, devices, and various therapies, with a particular emphasis on addressing unmet medical needs within the mission of the National Institute of Neurological Disorders and Stroke (NINDS). The funding mechanism consists of a two-phase cooperative agreement, with an initial planning phase (UG3) lasting up to one year, followed by a clinical trial phase (UH3) lasting a maximum of four years, totaling no more than five years for the entire project. Interested applicants, including educational institutions and nonprofits, must submit their proposals by January 9, 2025, and can reach out to the NIH OER Webmaster at grantsinfo@nih.gov for further assistance.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-21-237-Full-Announcement.html
    PAR-21-237.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has announced a funding opportunity titled "NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)" aimed at encouraging investigator-initiated efficacy clinical trials, specifically for neurological disorders. The funding mechanism, a UG3/UH3 cooperative agreement, consists of two phases: an initial planning phase (UG3) lasting up to one year and a clinical trial phase (UH3) lasting a maximum of four years, with a total project duration not exceeding five years. The trials must fulfill specific scientific milestones in the UG3 phase to transition to UH3. Eligible applicants include educational institutions, nonprofits, and government entities, with no limit on the number of applications, provided they are scientifically distinct. A critical focus is on trials addressing unmet medical needs, with detailed requirements for study design and oversight. The application process involves compliance with rigorous standards for data management, safety monitoring, and patient recruitment. Key dates for application submission are outlined, and budget requests should reflect the actual needs of the proposed study. Applicants are encouraged to establish collaborations with patient advocacy groups and consult with NINDS staff to refine their proposals. This initiative emphasizes advancing public health interventions through well-designed clinical research within the NINDS mission.
    Similar Opportunities
    NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Neurological Disorders and Stroke (NINDS), is offering a funding opportunity for investigator-initiated exploratory clinical trials under the UG3/UH3 mechanism. This initiative aims to support Phase 1 and Phase 2 clinical trials that address critical questions related to neurological disorders, focusing on studies involving drugs, biologics, devices, and early interventions. The program emphasizes rigorous research design and encourages diverse and innovative research teams, with grants potentially spanning up to five years, beginning with a planning phase before transitioning to execution. Interested applicants can find more information and application details at the provided link, with a submission deadline of March 10, 2025, and no cost-sharing or matching requirement.
    Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for prospective observational comparative effectiveness research (CER) in clinical neurosciences, specifically through the National Institute of Neurological Disorders and Stroke (NINDS). This initiative aims to encourage grant applications that investigate preventive strategies, diagnostic approaches, and various interventions, including drugs, devices, and therapies, that align with NINDS's mission. The funding mechanism follows a UG3/UH3 cooperative agreement structure, starting with a 2-year planning phase (UG3) that may transition into a 5-year observational study phase (UH3) upon meeting specific milestones. Interested applicants, including a diverse range of organizations, must submit their applications by May 7, 2025, and can find more information at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for small business concerns (SBCs) through the NINDS Exploratory Clinical Trials program (R43/R44), aimed at supporting investigator-initiated exploratory clinical trials related to neurological disorders. This program invites applications for studies that evaluate drugs, biologics, devices, or therapies, generating preliminary data to inform future clinical development, with a focus on enhancing diverse perspectives within research teams. Eligible U.S.-based SBCs can apply for funding caps of up to $295,924 for Phase I and $1,972,828 for Phase II, with applications due by September 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-311.html.
    NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the SIREN Neurologic Clinical Trials (UG3/UH3), aimed at developing multi-center clinical trials focused on neurological emergencies. This initiative encourages applications from a diverse range of entities, including universities, nonprofit organizations, and various community-serving institutions, to utilize the SIREN Network's infrastructure for efficient trial management, statistical support, and patient recruitment. The overarching goal is to enhance understanding and treatment of neurological emergencies through collaborative clinical research, ultimately improving patient outcomes and advancing healthcare practices. Interested applicants should note that the application deadline is March 6, 2026, and can find further details and guidelines at the provided NIH link or contact grantsinfo@nih.gov for inquiries.
    Clinical Trial Readiness for Functional Neurological Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for a funding opportunity titled "Clinical Trial Readiness for Functional Neurological Disorders (U01 Clinical Trial Optional)," aimed at enhancing clinical trial methodologies for Functional Neurological Disorders (FNDs). This initiative seeks to address critical challenges in the diagnosis and management of FNDs by encouraging the validation of biomarkers and clinical outcome assessments (COAs) that are specifically tailored for clinical trials. Given the significant healthcare burden posed by FNDs, which often require interdisciplinary approaches for effective management, this funding opportunity emphasizes the need for robust clinical evidence to improve treatment strategies and patient outcomes. Interested applicants, including a diverse range of organizations such as higher education institutions and community-based organizations, must submit their proposals by November 5, 2024, with funding contingent on NIH appropriations. For further inquiries, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)" aimed at supporting Small Business Concerns (SBCs) in conducting investigator-initiated exploratory clinical trials related to neurological disorders. This initiative encourages applications for Phase I and II studies focusing on drugs, biologics, devices, and therapies that align with the mission of the National Institute of Neurological Disorders and Stroke (NINDS), emphasizing the inclusion of a Plan for Enhancing Diverse Perspectives (PEDP) to foster innovation. The maximum funding amounts are $295,924 for Phase I and $1,972,828 for Phase II projects, with applications required to demonstrate readiness for eventual FDA regulatory approval. Interested applicants can begin submitting proposals on December 5, 2023, with the application deadline set for September 5, 2026; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)." This initiative aims to support multi-site exploratory and confirmatory clinical trials that focus on innovative interventions, biomarker validation, and ancillary studies related to stroke prevention, treatment, and recovery. The program emphasizes collaboration within the NIH StrokeNet infrastructure to enhance patient recruitment and trial execution, addressing critical public health issues associated with stroke. Interested applicants must submit their proposals by November 19, 2026, and can find additional information and application details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Limited Competition: Renewal of Existing NINDS-Supported Clinical Trial Cooperative Agreement Awards (U01 - Clinical Trials Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Neurological Disorders and Stroke (NINDS), is offering a limited competition for the renewal of existing clinical trial cooperative agreement awards (U01) that require additional time and resources to complete ongoing research on neurological disorders. This funding opportunity is specifically aimed at supporting extramural research efforts and emphasizes the importance of collaboration between NIH and award recipients to achieve significant advancements in the field. Eligible applicants include various federal entities, independent school districts, and tribal organizations, with the application submission period opening on February 5, 2025, and deadlines extending throughout the year. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-149.html.
    NINDS Research Education Programs for Residents and Fellows in Neurological Disorders and Stroke (UE5 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "NINDS Research Education Programs for Residents and Fellows in Neurological Disorders and Stroke" (UE5 Program) aimed at enhancing the training of clinician-scientists in the field of neurological disorders. This initiative seeks to support educational activities that provide research experiences and career development workshops, with a focus on preparing physicians to secure independent NIH research funding and transition into physician-scientists. The program is open to a variety of eligible applicants, including accredited medical schools, hospitals, and various educational institutions, with funding available for up to three increments totaling a maximum of 36 months, and an award ceiling of $850,000. Interested applicants should submit letters of intent and adhere to the application guidelines outlined in the full announcement, with the closing date for applications set for January 28, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Funding Opportunity Announcement (FOA) for the NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3), aimed at supporting research applications focused on planning and executing clinical trials related to dental, oral, and craniofacial health. This funding opportunity is structured in two phases: an initial one-year planning phase (UG3) followed by a potential five-year implementation phase (UH3), contingent upon meeting specific scientific milestones and feasibility requirements. The initiative seeks to expedite the development of evidence-based approaches to improve health outcomes in dentistry, emphasizing rigorous adherence to ethical and regulatory standards throughout the trial process. Interested applicants, including various higher education institutions and nonprofit organizations, must submit their applications by January 8, 2025, and can find additional information at the NIH grants website or contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for assistance.